{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T04:01:47Z","timestamp":1751860907712,"version":"3.41.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.diagmicrobio.2018.08.006","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T18:00:00Z","timestamp":1535047200000},"page":"85-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["In vitro activity of tedizolid against clinical isolates of Staphylococcus lugdunensis and Staphylococcus haemolyticus from Europe and the United States"],"prefix":"10.1016","volume":"93","author":[{"given":"David J.","family":"Farrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mekki","family":"Bensaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0005","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1128\/JCM.00846-17","article-title":"Is Staphylococcus lugdunensis significant in clinical samples?","volume":"55","author":"Argemi","year":"2017","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/23744235.2015.1122225","article-title":"Emergence of linezolid-resistant coagulase-negative staphylococci in an intensive care unit","volume":"48","author":"Balandin","year":"2016","journal-title":"Infect Dis (Lond)"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0015","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1128\/JCM.05563-11","article-title":"Staphylococcus haemolyticus as an important hospital pathogen and carrier of methicillin resistance genes","volume":"50","author":"Barros","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"27 Suppl","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0020","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.33321\/cdi.2003.27.23","article-title":"SENTRY antimicrobial surveillance program Asia-Pacific region and South Africa","author":"Bell","year":"2003","journal-title":"Commun Dis Intell Q Rep"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.diagmicrobio.2016.10.009","article-title":"Surveillance of tedizolid activity and resistance: in vitro susceptibility of gram-positive pathogens collected over 5 years from the United States and Europe","volume":"87","author":"Bensaci","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0030","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/JCM.01024-08","article-title":"Staphylococcus lugdunensis, a common cause of skin and soft tissue infections in the community","volume":"47","author":"Bocher","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0035","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1128\/AAC.01569-09","article-title":"Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges","volume":"54","author":"Brown","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0040","first-page":"1014","article-title":"Emergence and dissemination of a linezolid-resistant Staphylococcus capitis clone in Europe","volume":"72","author":"Butin","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"Pt 11","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0045","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1099\/jmm.0.043729-0","article-title":"Linezolid-resistant clinical isolates of meticillin-resistant coagulase-negative staphylococci and Enterococcus faecium from China","volume":"61","author":"Cai","year":"2012","journal-title":"J Med Microbiol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.diagmicrobio.2014.09.011","article-title":"Linezolid-resistant Staphylococcus haemolyticus and Staphylococcus hominis: single and double mutations at the domain V of 23S rRNA among isolates from a Rio de Janeiro hospital","volume":"80","author":"Chamon","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"year":"2015","series-title":"M07-A10. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved standard","author":"Clinical and Laboratory Standards Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0055"},{"year":"2017","series-title":"M100-S27. Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0060"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057096","article-title":"Cfr-mediated linezolid-resistance among methicillin-resistant coagulase-negative staphylococci from infections of humans","volume":"8","author":"Cui","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0070","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1099\/mic.0.000178","article-title":"Staphylococcus haemolyticus \u2013 an emerging threat in the twilight of the antibiotics age","volume":"161","author":"Czekaj","year":"2015","journal-title":"Microbiology"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0075","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijantimicag.2015.07.022","article-title":"Susceptibility trends including emergence of linezolid resistance among coagulase-negative staphylococci and meticillin-resistant Staphylococcus aureus from invasive infections","volume":"46","author":"Decousser","year":"2015","journal-title":"Int J Antimicrob Agents"},{"year":"2017","series-title":"Breakpoint tables for interpretation of MICs and zone diameters Version 7.1","author":"European Committee on Antimicrobial Susceptibility Testing","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0080"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0085","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkt331","article-title":"Cfr-mediated linezolid resistance in methicillin-resistant Staphylococcus aureus and Staphylococcus haemolyticus associated with clinical infections in humans: two case reports","volume":"69","author":"Fessler","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0090","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.diagmicrobio.2013.01.025","article-title":"An international activity and spectrum analysis of linezolid: ZAAPS program results for 2011","volume":"76","author":"Flamm","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.00036-07","article-title":"From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis","volume":"21","author":"Frank","year":"2008","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0100","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dks354","article-title":"The emerging problem of linezolid-resistant Staphylococcus","volume":"68","author":"Gu","year":"2013","journal-title":"J Antimicrob Chemother"},{"author":"JMI Laboratories","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0105"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-37923","article-title":"Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY antimicrobial surveillance program (1997-2001)","volume":"24","author":"Jones","year":"2003","journal-title":"Semin Respir Crit Care Med"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0115","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cit616","article-title":"Tedizolid for the management of human infections: in vitro characteristics","volume":"58","author":"Locke","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Pt 11","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0120","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1099\/jmm.0.034066-0","article-title":"Antibiotic susceptibility of coagulase-negative staphylococci (CoNS): emergence of teicoplanin-non-susceptible CoNS strains with inducible resistance to vancomycin","volume":"60","author":"Ma","year":"2011","journal-title":"J Med Microbiol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0125","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.bjid.2016.05.007","article-title":"Molecular epidemiology of coagulase-negative bloodstream isolates: detection of Staphylococcus epidermidis ST2, ST7 and linezolid-resistant ST23","volume":"20","author":"Martinez-Melendez","year":"2016","journal-title":"Braz J Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10096-011-1343-6","article-title":"Outbreak of linezolid-resistant Staphylococcus haemolyticus in an Italian intensive care unit","volume":"31","author":"Mazzariol","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"year":"2016","series-title":"Sivextro (Tedizolid Phosphate) Prescribing Information","author":"Merck & Co I","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0135"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0140","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijantimicag.2009.09.025","article-title":"Linezolid treatment of a prosthetic joint infection with Staphylococcus lugdunensis in a patient with multiple myeloma","volume":"35","author":"Merino","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0145","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhin.2016.07.012","article-title":"A clone of linezolid-resistant Staphylococcus epidermidis bearing the G2576T mutation is endemic in an Italian hospital","volume":"94","author":"Morroni","year":"2016","journal-title":"J Hosp Infect"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0155","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1159\/000363281","article-title":"Factors influencing linezolid-nonsusceptible coagulase-negative staphylococci dissemination among patients in the intensive care unit: a retrospective cohort study","volume":"59","author":"Papadimitriou-Olivgeris","year":"2013","journal-title":"Chemotherapy"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0160","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.eimc.2016.08.004","article-title":"Comparative activity of tedizolid against clinical isolates of linezolid-resistant coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus","volume":"35","author":"Perez-Parra","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"2 Suppl","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0165","first-page":"10","article-title":"Global view of antimicrobial resistance. Findings of the SENTRY antimicrobial surveillance program, 1997-1999","volume":"109","author":"Pfaller","year":"2001","journal-title":"Postgrad Med"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0170","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/mdr.2015.0064","article-title":"Susceptibility profile of Staphylococcus epidermidis and Staphylococcus haemolyticus isolated from blood cultures to vancomycin and novel antimicrobial drugs over a period of 12 years","volume":"22","author":"Pinheiro","year":"2016","journal-title":"Microb Drug Resist"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0175","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1128\/AAC.00458-12","article-title":"In vitro activity and microbiological efficacy of tedizolid (TR-700) against gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections","volume":"56","author":"Prokocimer","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0180","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/AAC.00076-10","article-title":"Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections","volume":"55","author":"Prokocimer","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0185","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0190","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1128\/JCM.01598-12","article-title":"Mechanisms of linezolid resistance among staphylococci in a tertiary hospital","volume":"51","author":"Quiles-Melero","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2018.08.006_bb0195","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jgar.2016.12.005","article-title":"Occurrence of linezolid-resistant Staphylococcus haemolyticus in two tertiary care hospitals in Mysuru, South India","volume":"8","author":"Rajan","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0200","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijantimicag.2012.10.017","article-title":"Improving linezolid use decreases the incidence of resistance among gram-positive microorganisms","volume":"41","author":"Ramirez","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0205","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.diagmicrobio.2014.08.011","article-title":"Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe","volume":"81","author":"Sahm","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0210","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1128\/AAC.00228-09","article-title":"In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent","volume":"53","author":"Schaadt","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"Pt 1","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0215","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1099\/jmm.0.05294-0","article-title":"Isolation and molecular characterization of multiresistant Staphylococcus sciuri and Staphylococcus haemolyticus associated with skin and soft-tissue infections","volume":"53","author":"Shittu","year":"2004","journal-title":"J Med Microbiol"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0220","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.03688-14","article-title":"Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections","volume":"59","author":"Shorr","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0225","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.diagmicrobio.2016.02.008","article-title":"In vitro activity of tedizolid against linezolid-resistant staphylococci and enterococci","volume":"85","author":"Silva-Del Toro","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0230","doi-asserted-by":"crossref","first-page":"e00894","DOI":"10.1128\/mBio.00894-14","article-title":"Mechanisms of linezolid resistance among coagulase-negative staphylococci determined by whole-genome sequencing","volume":"5","author":"Tewhey","year":"2014","journal-title":"MBio"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2018.08.006_bb0235","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1128\/AAC.00274-13","article-title":"Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins","volume":"57","author":"Thomson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.08.006_bb0240","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12941-014-0046-0","article-title":"Use of linezolid susceptibility test results as a surrogate for the susceptibility of gram-positive pathogens to tedizolid, a novel oxazolidinone","volume":"13","author":"Zurenko","year":"2014","journal-title":"Ann Clin Microbiol Antimicrob"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318302955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318302955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T14:14:18Z","timestamp":1751811258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318302955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0732889318302955"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.08.006","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of tedizolid against clinical isolates of Staphylococcus lugdunensis and Staphylococcus haemolyticus from Europe and the United States","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}